These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33710035)

  • 1. New-Onset of Inflammatory Bowel Disease in a Patient Treated With Teprotumumab for Thyroid Associated Ophthalmopathy.
    Ashraf DC; Jankovic I; El-Nachef N; Winn BJ; Kim GE; Kersten RC
    Ophthalmic Plast Reconstr Surg; 2021 Sep-Oct 01; 37(5):e160-e164. PubMed ID: 33710035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
    Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
    Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease.
    Safo MB; Silkiss RZ
    Am J Ophthalmol Case Rep; 2021 Jun; 22():101069. PubMed ID: 33817409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teprotumumab: First Approval.
    Markham A
    Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease.
    Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD
    Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Case of Teprotumumab Treatment in an Adolescent Patient With Thyroid Eye Disease.
    Radulovich N; Van Brummen A; Chambers C; Zhang M
    Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):e65-e67. PubMed ID: 38231594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired Epiblepharon Alleviated With Teprotumumab Treatment in Active Thyroid Eye Disease Patient.
    Chen KW; Phelps PO
    Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):e195-e196. PubMed ID: 34269764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teprotumumab-Induced Encephalopathy: A Rare Side Effect of a Novel Therapeutic.
    Yee MD; McCarthy J; Quinn B; Surani A
    WMJ; 2023 May; 122(2):134-137. PubMed ID: 37141481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teprotumumab for Asymmetric Thyroid Eye Disease.
    Ugradar S; Wang Y; Douglas R
    Ophthalmology; 2021 Oct; 128(10):1416. PubMed ID: 34556309
    [No Abstract]   [Full Text] [Related]  

  • 12. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ototoxicity and Teprotumumab.
    Highland J; Gordon S; Reddy D; Patel N
    Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.
    Chu M; Sung J; Song M; Song A; Song J
    J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?
    Bartalena L; Marinò M; Marcocci C; Tanda ML
    J Endocrinol Invest; 2022 Jul; 45(7):1455-1457. PubMed ID: 35403994
    [No Abstract]   [Full Text] [Related]  

  • 16. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.
    Hwang CJ; Nichols EE; Chon BH; Perry JD
    Eur J Ophthalmol; 2022 May; 32(3):NP46-NP49. PubMed ID: 33525898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
    Slentz DH; Nelson CC; Smith TJ
    Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
    Ding AS; Mahoney NR; Campbell AA; Creighton FX
    Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.
    Phansalkar R; Lu T; Alyono J; Lee J; Dosiou C; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):e101-e104. PubMed ID: 36877549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
    Smith TJ
    J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.